The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Breast Cancer MORE >>

The primary endpoint for the phase III SOLAR-1 trial has been met, with improved progression-free survival seen with the combination of alpelisib and fulvestrant compared with fulvestrant alone in postmenopausal women and men with HR-positive, HER2-negative, PIK3CA-mutant advanced or metastatic breast cancer that had progressed after aromatase inhibitor treatment with or without a CDK4/6 inhibitor.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.